Stereotaxis Ord Stock Price, News & Analysis

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced its participation in two upcoming investor conferences in New York City this September. CEO David Fischel will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10th, 2025, at 8:00 am EDT, and attend the Lake Street Capital 9th Annual Best Ideas Growth Conference on September 11th, 2025.

The company, which has treated over 150,000 patients globally with its robotic technology, will discuss its technological and commercial progress in its growth strategy. One-on-one meetings with Mr. Fischel can be arranged through conference registration.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, will showcase its technology at the upcoming HRX digital health conference from September 4-6, 2025, in Atlanta.

CEO David Fischel will participate in a roundtable discussion on September 5th at 3:45 PM EDT. Following this, at 4:45 PM EDT, a panel of electrophysiologists will lead a session titled "Cutting-Edge Ablation Techniques That Challenge Traditional Methods and Improve Patient Outcomes", exploring robotics, AR/VR, AI, and automation in cardiac care.

The company's technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics, reported its Q2 2025 financial results with significant growth. Total revenue reached $8.8 million, up 95% year-over-year and 18% sequentially. System revenue was $3.0 million, while recurring revenue grew 35% to $5.8 million.

The company achieved a notable milestone with FDA clearance of MAGiC Sweep, its first interventional catheter approval in nearly 20 years. Gross margin was 52%, with recurring revenue margin at 68% and system margin at 22%. The quarter ended with $7.0 million in cash, subsequently strengthened by a $12.5 million strategic financing in July.

Management reiterated expectations of double-digit revenue growth for 2025, projecting $2-3 million quarterly system revenue and recurring revenue scaling to $7 million by Q4 2025.

Stereotaxis (NYSE:STXS), a pioneer in surgical robotics, has received FDA 510(k) clearance for its MAGiC Sweep™ catheter, the world's first robotically navigated high-density electrophysiology mapping catheter. The innovative device features 20 electrodes for detailed cardiac mapping and integrates with Stereotaxis' Robotic Systems.

The MAGiC Sweep catheter offers significant advantages including efficient high-density mapping, extended reach and precision, atraumatic design, and improved anatomical accuracy. This marks Stereotaxis' first FDA clearance for an interventional catheter in nearly 20 years and represents a crucial milestone in the company's comprehensive innovation strategy for advancing robotics in electrophysiology.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, will release its Q2 2025 financial results on August 7, 2025 after market close. The company will host a conference call and webcast at 4:30 p.m. ET to discuss results and corporate developments.

Stereotaxis' technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions. The company specializes in developing robotic systems, instruments, and information solutions for interventional laboratories, focusing on enhancing physician care delivery with robotic precision and safety.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has announced a $12.5 million registered direct offering of common stock at $2.00 per share. The offering is led by a strategic industry partner and select institutional investors.

The financing will be completed in two closings: an initial $8.5 million closing around July 18, 2025, and a second $4.0 million closing by November 25, 2025. Lake Street Capital Markets LLC serves as the exclusive placement agent. The proceeds will support product commercialization, research and development, and other corporate purposes.

Stereotaxis technology has been used to treat over 150,000 patients globally across the United States, Europe, Asia, and other regions.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics, announced the publication of first clinical results for its MAGiC catheter in the Journal of Interventional Cardiac Electrophysiology. The prospective multi-center study demonstrated an impressive 94% acute efficacy rate in treating various heart arrhythmias.

The study, conducted at Copenhagen University Hospital Rigshospitalet and Vilnius University Hospital Santaros Klinikos, included 67 patients with various arrhythmias. The average procedure time was 83 minutes skin-to-skin, with a low procedure-related adverse event rate of 1.5%. Patient enrollment continues with approximately 100 patients enrolled to date, with efficacy assessments ongoing for up to one year.

The MAGiC catheter, designed for robotically-navigated magnetic ablation procedures, showed notable improvements in stability, eliminating the need for sheaths for catheter support. The technology has already been utilized in treating over 150,000 patients across leading hospitals globally.

Stereotaxis (NYSE: STXS) reported Q1 2025 financial results with total revenue of $7.5 million, up 9% year-over-year. Recurring revenue grew 29% to $5.5 million, while system revenue decreased to $2.0 million from $2.6 million. The company reported a net loss of $5.8 million and ended the quarter with $10.7 million in cash and no debt. Key highlights include initial MAGiC commercialization in Europe, successful GenesisX demonstrations, and progress on regulatory efforts. Management reiterated expectations for double-digit revenue growth in 2025, projecting system revenue of $2-3 million per quarter and recurring revenue scaling to $7 million by Q4. The company maintains six active regulatory reviews and anticipates significant adoption of GenesisX pending regulatory approval.

Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular intervention, has scheduled its first quarter 2025 financial results release for May 12, 2025 after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. EST to discuss results and corporate developments.

Investors can access the live call by dialing 800-715-9871 (US/Canada) or 1-646-307-1963 (International) with pass code 4794777. A webcast will be available through the investor relations section of Stereotaxis' website, with replay access available for one month after the call.

Stereotaxis' technology has been utilized in treating over 150,000 patients globally across the United States, Europe, Asia, and other regions.